Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia
Filip Matthijssens, … , Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska
Filip Matthijssens, … , Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska
Published February 8, 2021
Citation Information: J Clin Invest. 2021;131(6):e141566. https://doi.org/10.1172/JCI141566.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 10

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia

  • Text
  • PDF
Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2) was upregulated in high-risk T-ALL with KMT2A rearrangements (KMT2A-R) or an immature immunophenotype. In KMT2A-R cells, we identified RUNX2 as a direct target of the KMT2A chimeras, where it reciprocally bound the KMT2A promoter, establishing a regulatory feed-forward mechanism. Notably, RUNX2 was required for survival of immature and KMT2A-R T-ALL cells in vitro and in vivo. We report direct transcriptional regulation of CXCR4 signaling by RUNX2, thereby promoting chemotaxis, adhesion, and homing to medullary and extramedullary sites. RUNX2 enabled these energy-demanding processes by increasing metabolic activity in T-ALL cells through positive regulation of both glycolysis and oxidative phosphorylation. Concurrently, RUNX2 upregulation increased mitochondrial dynamics and biogenesis in T-ALL cells. Finally, as a proof of concept, we demonstrate that immature and KMT2A-R T-ALL cells were vulnerable to pharmacological targeting of the interaction between RUNX2 and its cofactor CBFβ. In conclusion, we show that RUNX2 acts as a dependency factor in high-risk subtypes of human T-ALL through concomitant regulation of tumor metabolism and leukemic cell migration.

Authors

Filip Matthijssens, Nitesh D. Sharma, Monique Nysus, Christian K. Nickl, Huining Kang, Dominique R. Perez, Beatrice Lintermans, Wouter Van Loocke, Juliette Roels, Sofie Peirs, Lisa Demoen, Tim Pieters, Lindy Reunes, Tim Lammens, Barbara De Moerloose, Filip Van Nieuwerburgh, Dieter L. Deforce, Laurence C. Cheung, Rishi S. Kotecha, Martijn D.P. Risseeuw, Serge Van Calenbergh, Takeshi Takarada, Yukio Yoneda, Frederik W. van Delft, Richard B. Lock, Seth D. Merkley, Alexandre Chigaev, Larry A. Sklar, Charles G. Mullighan, Mignon L. Loh, Stuart S. Winter, Stephen P. Hunger, Steven Goossens, Eliseo F. Castillo, Wojciech Ornatowski, Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska

×

Figure 1

RUNX2 is upregulated in T-ALL harboring KMT2A-R and/or immature/ETP phenotype.

Options: View larger image (or click on image) Download as PowerPoint

RUNX2 is upregulated in T-ALL harboring KMT2A-R and/or immature/ETP phe...
(A) RUNX2 expression across distinct molecular/genetic subtypes of T-ALL identified in a cohort of 242 pediatric and young adult T-ALL patients (8). (B) RUNX2 mRNA levels in HOXA-deregulated T-ALL with chromosomal rearrangements involving the KMT2A gene (KMT2A-R, n = 11; other HOXA, n = 21) (8). (C) RUNX2 expression in 189 T-ALL samples classified based on ETP (n = 19), near-ETP (n = 24), and non-ETP (n = 146) phenotype by flow cytometry (8). (D and E) RUNX2 mRNA and protein levels in T-ALL cell lines (n = 9). (F) RUNX2 mRNA expression in primary T-ALL samples depending on maturation arrest (n = 11) according to European Group for the Immunological Characterization of Acute Leukemias (EGIL) classification (103). (G) qRT-PCR analyses of RUNX2 mRNA in primary T-ALL samples with or without KMT2A-R (KMT2A-R, n = 12; others, n = 13). Data are shown as mean ± SD, using 3 independent experiments. (H) Immunoblotting for RUNX2 protein levels in primary T-ALL samples (n = 9). Red font indicates KMT2A-R samples. (I) RUNX2 protein expression in PDX samples (n = 14) by flow cytometry. (A and C) Kruskal-Wallis with Dunn’s multiple comparison test; (B) unpaired Mann-Whitney U test. *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 16 X users
51 readers on Mendeley
See more details